ASCO 2025
Interviews and expert commentary from ASCO 2025 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
30 June 2025
11:51
Audio Journal of Oncology
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon
10 June 2025
7:24
Audio Journal of Oncology
Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy
SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival amon
13 March 2025
22:08